You are here

"Retrospective Study to Identify Clinical Factors Related to a High Benefit of Axitinib in mRCC"

Last updated on April 12, 2019

FOR MORE INFORMATION
Study Location
Hospital Universitario Rey Juan carlos
Mostoles, Madrid, 28933 Spain
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Renal Cell Carcinoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Age ≥ 18 years

- Patients with advanced or metastatic renal cell carcinoma, histologically
confirmed, with at least one radiological response assessment

- Patients who had received Axitinib treatment in second or further line with a PFS
≥9 months or DP (disease progression) at the first tumor assessment.

- For the patients alive at the moment of the inclusion, patients must have a
signed informed consent document

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Axitinib received out of the approved indication Patients who do not meet any of the
inclusion criteria

NCT03538717
Pfizer
Active, not recruiting
"Retrospective Study to Identify Clinical Factors Related to a High Benefit of Axitinib in mRCC"

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now